Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations

Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase.

(2015) Hongdo Do et al.   Oncotarget

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice

(2013) L Heinzerling et al.   BRITISH JOURNAL OF CANCER

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

(2013) Silvy da Rocha Dias et al.   EUROPEAN JOURNAL OF CANCER

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

(2013) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

The somatic affairs ofBRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations

(2013) Giovanni Ponti et al.   JOURNAL OF CLINICAL PATHOLOGY

KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics

(2013) Markus Rechsteiner et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib

(2013) Fernando Lopez-Rios et al.   PLoS One

Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAFV600

(2013) Alexander Skorokhod et al.   PLoS One

Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma

(2012) Georgina V. Long et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions

(2012) Klaus J. Busam et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection ofBRAFV600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma

(2012) Steven Anderson et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

High-Resolution Melting Analysis as a Sensitive Prescreening Diagnostic Tool to Detect KRAS, BRAF, PIK3CA, and AKT1 Mutations in Formalin-Fixed, Paraffin-Embedded Tissues

(2012) Jasmin Teresa Ney et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma

(2012) Harkanwal Halait et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis

(2012) Shanxiang Shen et al.   Diagnostic Pathology

BRAF inhibitor activity in V600R metastatic melanoma

(2012) Oliver Klein et al.   EUROPEAN JOURNAL OF CANCER

A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas

(2012) Sylwia Jancik et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Melanoma: New Insights and New Therapies

(2012) Vasiliki A. Nikolaou et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results

(2012) Guoli Chen et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Detection of BRAF p.V600E Mutations in Melanomas

(2012) Emeline Colomba et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas

(2012) Johanne Lade-Keller et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1

(2012) Alexander Skorokhod et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

(2012) B. Sen et al.   Science Translational Medicine

Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma

(2012) Jonathan L. Curry et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

(2012) Kimberly Brown Dahlman et al.   Cancer Discovery

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

(2011) David Capper et al.   ACTA NEUROPATHOLOGICA

Whole Cancer Genome Sequencing by Next-Generation Methods

(2011) Jeffrey S. Ross et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

(2011) Qing Dong et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

(2011) Paul K. Paik et al.   JOURNAL OF CLINICAL ONCOLOGY

RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

(2011) Patrick A. Oberholzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Allelic Discrimination by dHPLC, HRM, and TaqMan in the Detection of BRAF Mutation V600E

(2011) Pablo Carbonell et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pyrosequencing enhancement for better detection limit and sequencing homopolymers

(2010) Min Gong et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations

(2010) Athanasios C. Tsiatis et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

BRAF Signaling and Targeted Therapies in Melanoma

(2009) Nathalie Dhomen et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

(2009) Jolien Tol et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

High Quality Assessment of DNA Methylation in Archival Tissues from Colorectal Cancer Patients Using Quantitative High-Resolution Melting Analysis

(2009) Marija Balic et al.   JOURNAL OF MOLECULAR DIAGNOSTICS